United States: The FDA Gets Social: Interpreting Its Draft Social Media Guidance

Last Updated: January 28 2014
Article by Sharon Klein and Melissa L. Nuñez

The U.S. Food and Drug Administration (FDA) recently released draft guidance that paves the way for regulated companies to harness the power of social media.1 This draft guidance addresses how FDA-regulated manufacturers, packers and distributors of prescription human and animal drugs and biologics ("regulated firms") can comply with regulatory requirements for postmarketing submissions of interactive promotional materials. Regulated firms have been shut out of real-time communications via social networking sites due to restrictions on promotional activities. The new guidance, while not yet finalized, indicates that regulated firms may jump into this market in the coming months. The FDA has requested comments on the draft guidance by April 14, 2014.


Generally, regulated firms are required to submit all promotional labeling and advertising materials to the FDA at the time of their initial dissemination or publication. In the case of real-time social media (think: blogs, Facebook updates, tweets, podcasts and online communities), submission at the time of initial dissemination would be all but impossible. Now, the FDA has issued guidance for submission of most materials after-the-fact.

What Is 'Interactive Promotional Media'?

"Interactive promotional media" is the term the FDA is using to refer to real-time social media promotions by regulated firms. The key guidance relating to determining whether a regulated firm is responsible for interactive promotional media is as follows:

1. Regulated firms are responsible for promotional communications on sites that are owned, controlled, created, influenced or operated by or on behalf of the firm.

What This Means: Promotional content posted to company-sponsored sites is clearly covered and must be submitted to the FDA. The trickier issue is whether a regulated firm influences or has control over a site owned by a third party. The FDA's threshold is very low; the FDA states that a firm is responsible for promotion on a third-party site if it has "any control or influence" (emphasis added) on the third-party site. Indeed, the influence can be limited in scope and still trigger responsibility; editorial, preview or review privileges will suffice. Notably, financial support alone does not trigger responsibility, so long as it is not coupled with other influence.

If a regulated firm does not have influence over a third-party site, it need only submit to the FDA the promotional content it provided that site but not everything on the third-party site. If a regulated firm does have such influence, it will be responsible for submitting the promotion, along with the surrounding pages, to the FDA and otherwise meet the new postmarketing submission requirements.

Pepper Point: To reduce submission burdens to the FDA, regulated firms should not request previews of third-party Web sites or direct the particular placement of promotional materials on third-party Web sites.

2. Regulated firms may be responsible for content on third-party sites if it is generated by their employees or agents or if the regulated firm has control over or influence on the site.

What This Means: Comments by employees and other agents acting on a regulated firm's behalf and made on third-party Web sites about the regulated firm's products are attributed to the regulated firm for purposes of FDA submission. For example, if a paid speaker makes a comment on a third-party site, that material should be submitted to the FDA.

Pepper Point: Regulated firms should consider training employees so they understand the possible consequences of their online activity when acting on behalf of the regulated firm. Additionally, regulated firms should take steps to distance themselves from online content not under their control.

3. Regulated firms are responsible for content generated by employees and agents acting on their behalf to promote the regulated firm's products.

What This Means: Content placed online by employees and agents that promotes a regulated firm's products must be submitted to the FDA pursuant to the new postmarketing guidance. The FDA has also recommended that regulated firms clearly identify content generated by such employees and agents. Notably, the FDA will not "ordinarily" hold regulated firms responsible for user-generated content on firm-owned or controlled venues as long as the user has no affiliation with the regulated firm and the regulated firm had no influence on the user-generated content.

Pepper Point: Regulated firms should strictly police the content its employees and agents put on the Internet on their behalf and consider including a unique identifier, such as a logo, to clearly identify sponsored content. Consider including a pre-approval requirement for social media advertising in all contracts with advertisers.

Submission of 'Interactive Promotional Media' to the FDA

1. Regulated firms must submit sponsored sites to the FDA at the time of initial display.

What This Means: If a regulated firm creates or sponsors a Web site that will include interactive promotional media, it must submit a comprehensive static product Web site with the real-time or interactive components to the FDA at the time of initial display. The submission will include information that will allow the FDA to review the content and features of the site. Any changes to the site must be resubmitted to the FDA.

Pepper Point: Regulated firms should limit changes to Web sites or make multiple changes at one time to limit resubmissions to the FDA.

2. Regulated firms must submit the home page, the interactive or real-time communications and the regulated firm's first communication for any third-party sites that contain regulated interactive promotional media.

What This Means: If a regulated firm's participation in a third-party site is limited to interactive or real-time communications, it must submit to the FDA: (1) the homepage of the third-party site, (2) the interactive page(s) of the site, and (3) the regulated firm's first communication. The submission process for continued participation of regulated firms on such sites is streamlined in the case of "unrestricted" sites (sites that are publicly viewable and do not require a password or subscription).

3. Regulated firms must submit monthly updates to the FDA for all non-restricted sites.

What This Means: Regulated firms must make a monthly filing with the FDA to disclose all non-restricted sites that contain interactive or real-time communications. The filing will include, for each site: (1) the name, (2) URL, (3) date range, and (4) a cross-reference to the date of the most recent submission of the site. Notification is also required when a regulated firm ceases activity on a site.

Pepper Point: The FDA is allowing one filing per month for all sponsored sites, rather than a filing for each such site, which cuts down on paperwork.

4. Regulated firms must submit more detailed information for restricted sites.

What This Means: If sites with interactive promotional material are restricted (i.e., require a password or subscription) and are therefore not easily monitored by the FDA, regulated firms must submit more detailed information in their monthly filings. This includes all content related to the discussion, which may include independent user-generated content, to adequately provide context to facilitate the FDA's review. Screenshots and other visual representations of the actual site, including the real-time communications, must also be submitted. Additionally, the FDA has recommended that regulated firms take formatting factors into account when submitting materials in order to facilitate the FDA's review. Such factors include appearance, layout and visual impression.

Pepper Point: Regulated firms should take the greater disclosure burden into account in determining whether to utilize restricted sites for promotional materials.


1. "Guidance for Industry: Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics" can be found at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM381352.pdf.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Melissa L. Nuñez
Similar Articles
Relevancy Powered by MondaqAI
Strasburger & Price, L.L.P.
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Strasburger & Price, L.L.P.
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions